Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study

G. Mazziotti, C. Battista, F. Maffezzoni, S. Chiloiro, E. Ferrante, N. Prencipe, L. Grasso, F. Gatto, R. Olivetti, M. Arosio, M. Barale, A. Bianchi, M. Cellini, I. Chiodini, L. De Marinis, G. Del Sindaco, C. Di Somma, A. Ferlin, E. Ghigo, A. GiampietroS. Grottoli, E. Lavezzi, G. Mantovani, E. Morenghi, R. Pivonello, T. Porcelli, M. Procopio, F. Pugliese, A. Scillitani, A.G. Lania

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of antiosteoporotic drugs in this clinical setting. OBJECTIVE: To evaluate whether in real-life clinical practice bone active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. STUDY DESIGN: Retrospective, longitudinal study including 9 tertiary care endocrine units. PATIENTS AND METHODS: Two hundred and forty-eight patients with acromegaly (104 males; mean age 56.00 ± 13.60 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). RESULTS: During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio [OR] 3.75; P 
Original languageEnglish
JournalJ. Clin. Endocrinol. Metab.
Volume105
Issue number9
DOIs
Publication statusPublished - 2020

Keywords

  • NEUROSCIENZE
  • STUDIO CLINICO
  • RIS

Fingerprint Dive into the research topics of 'Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study'. Together they form a unique fingerprint.

Cite this